News & Views
Milestone reached in Target Discovery Alliance
Jan 05 2023
Since entering a multi-project target discovery collaboration in January 2020, when PhoreMost deployed its phenotypic screening platform, SITESEEKER®, towards disease-relevant pathways selected by Boehringer Ingelheim, PhoreMost has triggered a milestone payment, achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first-in-class therapies to transform patients’ lives.
“The success of this project to date provides significant validation of our SITESEEKER platform and its capabilities in novel target discovery and is testament to the expertise and great collaborative efforts of the teams at both PhoreMost and Boehringer Ingelheim. We are proud to contribute to the development of much needed new therapies for patients by delivering on this first key milestone and look forward to continuing this very fruitful partnership” said Dr. Neil Torbett, Chief Executive Officer, PhoreMost.
The development of potential new therapies will now be continued at Boehringer Ingelheim leading to possible further success based pre-clinical, clinical and commercial milestone payments.
Further information online
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
Apr 22 2024 Marrakech, Morroco
Making Pharmaceuticals Exhibition & Conference
Apr 23 2024 Coventry, UK
Apr 23 2024 Kintex, South Korea
Apr 23 2024 Seoul, South Korea
Apr 24 2024 Jakarta, Indonesia